P2Y1 and P2Y12 are the two platelet purinergic receptors for adenosine diphosphate (ADP). Concomitant activation of P2Y1 and P2Y12 is essential for ADP‐induced platelet aggregation. In addition, ADP/P2Y12 amplifies the aggregation and secretion induced by other agonists and stabilizes platelet aggregates. Therefore, P2Y12 plays a key role in the formation of the hemostatic plug and the pathogenesis of arterial thrombi. Patients with defects of P2Y12 have a bleeding diathesis. Drugs that inhibit ADP–P2Y12‐induced platelet aggregation are very effective antithrombotic drugs.
Platelet Receptors and Drug Targets: P2Y(12) / M. Cattaneo - In: Antiplatelet Therapy in Cardiovascular Disease / [a cura di] R. Waksman, P.A. Gurbel, M.A. Gaglia. - [s.l] : Wiley Blackwell, 2014. - ISBN 9781118493984. - pp. 14-20 [10.1002/9781118493984.ch3]
Platelet Receptors and Drug Targets: P2Y(12)
M. Cattaneo
2014
Abstract
P2Y1 and P2Y12 are the two platelet purinergic receptors for adenosine diphosphate (ADP). Concomitant activation of P2Y1 and P2Y12 is essential for ADP‐induced platelet aggregation. In addition, ADP/P2Y12 amplifies the aggregation and secretion induced by other agonists and stabilizes platelet aggregates. Therefore, P2Y12 plays a key role in the formation of the hemostatic plug and the pathogenesis of arterial thrombi. Patients with defects of P2Y12 have a bleeding diathesis. Drugs that inhibit ADP–P2Y12‐induced platelet aggregation are very effective antithrombotic drugs.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
